Reliance on Advocacy is the Symptom Not the Disease.
作者信息
Gerido Lynette Hammond
机构信息
University of Michigan School of Public Health.
出版信息
Am J Bioeth. 2023 Jul;23(7):86-88. doi: 10.1080/15265161.2023.2207540.
Abstract
摘要
相似文献
1
Reliance on Advocacy is the Symptom Not the Disease.依赖宣传是症状而非疾病。
Am J Bioeth. 2023 Jul;23(7):86-88. doi: 10.1080/15265161.2023.2207540.
2
Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care.罕见病、倡导和正义：研究和临床护理中的交叉差异。
Am J Bioeth. 2023 Jul;23(7):17-26. doi: 10.1080/15265161.2023.2207500. Epub 2023 May 19.
3
Social justice advocacy in nursing: what is it? How do we get there?护理中的社会正义倡导：它是什么？我们如何实现它？
Creat Nurs. 2011;17(2):63-7. doi: 10.1891/1078-4535.17.2.63.
4
Integrating social justice advocacy into a family health team: Successes and lessons learned.将社会正义倡导融入家庭健康团队：成功经验和教训。
Can Fam Physician. 2021 Dec;67(12):923-929. doi: 10.46747/cfp.6712923.
5
The Other Side of the Self-Advocacy Coin: How For-Profit Companies Can Divert the Path to Justice in Rare Disease.自我维权的另一面：营利性公司如何在罕见病领域偏离正义之路。
Am J Bioeth. 2023 Jul;23(7):88-91. doi: 10.1080/15265161.2023.2207521.
6
Social Justice and Advocacy for Transgender and Gender-Diverse Clients.为跨性别和性别多样化客户提供社会正义与倡导服务。
Psychiatr Clin North Am. 2017 Mar;40(1):1-13. doi: 10.1016/j.psc.2016.10.009. Epub 2016 Dec 12.
7
The Dangers of Social Justice Advocacy.社会正义倡导的危险。
Soc Work. 2019 Jan 1;64(1):87-90. doi: 10.1093/sw/swy047.
8
Critiquing the Critique of Advocacy.对倡导之批判的批判
Am J Bioeth. 2023 Jul;23(7):97-99. doi: 10.1080/15265161.2023.2208073.
9
Rare Disease, Advocacy, and Caregiver Burnout.罕见病、宣传倡导与照护者倦怠
Am J Bioeth. 2023 Jul;23(7):91-94. doi: 10.1080/15265161.2023.2207509.
10
Toward a critical response to HIV criminalization: remarks on advocacy and social justice.对将感染艾滋病毒定为犯罪的批判性回应：关于宣传与社会正义的评论
J Assoc Nurses AIDS Care. 2012 Jan-Feb;23(1):11-5. doi: 10.1016/j.jana.2011.08.012. Epub 2011 Nov 6.
引用本文的文献
1
Building Better Medicine: Translational Justice and the Quest for Equity in US Healthcare.打造更优质的医学：转化正义与美国医疗保健中的公平追求
Am J Bioeth. 2025 Jun;25(6):11-25. doi: 10.1080/15265161.2025.2457713. Epub 2025 Feb 23.
2
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials.提高罕见病临床试验中的多样性、公平性、包容性和可及性。
Pharmaceut Med. 2024 Jul;38(4):261-276. doi: 10.1007/s40290-024-00529-8. Epub 2024 Jul 9.
本文引用的文献
1
Big advocacy, little recognition: the hidden work of Black patients in precision medicine.大力倡导，鲜少认可：黑人患者在精准医疗中的隐性工作
J Community Genet. 2023 Dec;14(6):657-665. doi: 10.1007/s12687-023-00673-9. Epub 2023 Sep 29.
2
Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care.罕见病、倡导和正义：研究和临床护理中的交叉差异。
Am J Bioeth. 2023 Jul;23(7):17-26. doi: 10.1080/15265161.2023.2207500. Epub 2023 May 19.
3
From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases.从“应当”到“是”：罕见病患者及家属权益倡导中的价值彰显
Am J Bioeth. 2021 Dec;21(12):1-3. doi: 10.1080/15265161.2021.1996801.
4
Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity.比较美国联邦政府和基金会对镰状细胞病和囊性纤维化研究的资助，以及与研究生产力相关的因素。
JAMA Netw Open. 2020 Mar 2;3(3):e201737. doi: 10.1001/jamanetworkopen.2020.1737.
5
Vulnerability and unmet health care needs. The influence of multiple risk factors.脆弱性与未满足的医疗保健需求。多种风险因素的影响。
J Gen Intern Med. 2005 Feb;20(2):148-54. doi: 10.1111/j.1525-1497.2005.40136.x.
Zotero 插件